Unicycive OLC CRL: The CMC Failure Behind a Biotech Selloff
The CMC Execution Crisis: Why Unicycive’s OLC CRL Is a Warning Shot for Every Indian CDMO | Witfire Elite View Witfire Elite CMC & Manufacturing Case Studies CDMO Strategy Long Read Pharma Market Case Studies Witfire Elite View The CMC Execution Crisis Why Unicycive’s OLC CRL Is a Warning Shot for Every Indian CDMO The FDA did not reject Oxylanthanum…
Trending News
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 | Witfire Elite View…
Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Revolution Medicines Daraxonrasib: The $4.3B Autopsy | Witfire Elite View Witfire Elite Oncology…
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
The stock market is now looking at the US-Israel-Iran conflict through a sharper…
Editorial picks
Unicycive OLC CRL: The CMC Failure Behind a Biotech Selloff
The CMC Execution Crisis: Why Unicycive’s OLC CRL Is a Warning Shot for Every Indian CDMO | Witfire Elite View Witfire Elite CMC & Manufacturing Case Studies CDMO Strategy Long Read Pharma Market Case Studies Witfire Elite View The CMC Execution Crisis Why Unicycive’s OLC CRL Is a Warning Shot…
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Categories
Investments
business news
Entrepreneurship
Startups
June, 2026
Chokepoints & Catalysts — Vol. I, No. 1
Five intelligence-led analyses on how FDA decisions, geopolitical chokepoints, and policy shifts are repricing global pharma—covering GSK’s Nuvalent acquisition, Replimune’s RP1, India’s CRO opportunity, API dependence, and Lilly’s Germany investment cut.
Around The World
Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell
Viridian’s Lumvoa Broke Tepezza’s Monopoly. Now Viridian Has to Prove It Can Sell | Witfire Elite View Witfire Elite Competitive Strategy Case Studies Launch Execution Long Read Pharma Market Case Studies Witfire Elite View Lumvoa Broke Tepezza’s Monopoly Now Viridian Has to Prove It Can Sell Viridian’s Lumvoa approval is not only a new thyroid eye disease launch. It is…
Pharma News
Unicycive OLC CRL: The CMC Failure Behind a Biotech Selloff
The CMC Execution Crisis: Why Unicycive’s OLC CRL Is a Warning Shot for Every Indian CDMO | Witfire…
AlzeCure ACD856 QuantumCell Deal: $2.2B Risk Transfer in Alzheimer’s
AlzeCure’s $2.2 Billion NeuroRestore Deal Is Not an Alzheimer’s Victory. It Is a Risk Transfer | Witfire Elite…
Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell
Viridian’s Lumvoa Broke Tepezza’s Monopoly. Now Viridian Has to Prove It Can Sell | Witfire Elite View Witfire…